NTRK1 and ovarian carcinoma: The phase II LEAP-005 study evaluated efficacy and safety of lenvatinib, an antiangiogenic multiple receptor tyrosine kinase inhibitor, plus pembrolizumab in patients with heavily pretreated ovarian cancer.